Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression

被引:35
|
作者
Kuge, Y [1 ]
Katada, Y
Shimonaka, S
Temma, T
Kimura, H
Kiyono, Y
Yokota, C
Minematsu, K
Seki, K
Tamaki, N
Ohkura, K
Saji, H
机构
[1] Kyoto Univ, Grad Sch Pharmceut Sci, Dept Pathofunct Bioanal, Kyoto, Japan
[2] Kyoto Univ Hosp, Fac Med, Radioisotopes Res Lab, Kyoto 6068507, Japan
[3] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[4] Natl Cardiovasc Ctr, Res Inst, Cerebrovasc Lab, Osaka 5658565, Japan
[5] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[6] Hokkaido Univ, Cent Inst Isotope Sci, Sapporo, Hokkaido 0608638, Japan
[7] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan
[8] Hokkaido Univ, Fac Pharmaceut Sci Hlth Sci, Dept Radiopharmaceut Chem, Sapporo, Hokkaido 0610293, Japan
关键词
cyclooxygenase-2 (COX-2); inhibitor; radioiodination; SPECT; radiopharmaceutical;
D O I
10.1016/j.nucmedbio.2005.10.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Although several COX-2 inhibitors have recently been radiolabeled, their potential for imaging COX-2 expression remains unclear. In particular, the sulfonamide moiety of COX-2 inhibitors may cause slow blood clearance of the radiotracer, due to its affinity for carbonic anhydrase (CA) in erythrocytes. Thus, we designed a methyl sulfone-type analogue, 5-(4-iodophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl-1H-pyrazole (IMTP). In this study, the potential of radioiodinated IMTP was assessed in comparison with a I-125-labeled celecoxib analogue with a sulfonamide moiety (I-125-IATP). Methods: The COX inhibitory potency was assessed by measuring COX-catalyzed oxidation by hydrogen peroxide. The biodistribution of I-125-IMTP and I-125-IATP was determined by the ex vivo tissue counting method in rats. Distribution of the labeled compounds to rat blood cells was measured. Results: The COX-2 inhibitory potency of IMTP (IC50=5.16 mu M) and IATP (IC50=8.20 mu M) was higher than that of meloxicam (IC50-29.0 mu M) and comparable to that of SC-58125 (IC50=1.36 mu M). The IC50 ratios (COX-1/COX-2) indicated the high isoform selectivity of IMTP and IATP for COX-2. Significant levels of I-125-IMTP and 125 MATP were observed in the kidneys and the brain (organs known to express COX-2). The blood clearance of I-125-IMTP was much faster than that of I-125-IATP. Distribution of (125) I-IATP to blood cells (88.0%) was markedly higher than that of I-125-IMTP (18.1%), which was decreased by CA inhibitors. Conclusions: Our results showed a high inhibitory potency and selectivity of IMTP for COX-2. The substitution of a sulfonamide moiety to a methyl sulfone moiety effectively improved the blood clearance of the compound, indicating the loss of the cross reactivity with CA in I-125-IMTP. I-123-IMTP may be a potential SPECT radiopharmaceutical for COX-2 expression. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [21] Aspirin and cyclooxygenase-2 inhibitors
    Armstrong, TA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (14) : 1481 - 1481
  • [22] Selective Cyclooxygenase-2 Inhibitors: Design and Synthesis
    Xin Sheng LEI
    Zong Ru GUO
    Ling Bo QU
    Qi Qing ZHU(Institute of Materia Medica. Chinese Academy of Medical SciencesAnd Peking Union Medical College. Beijing 100050)
    Chinese Chemical Letters, 1999, (06) : 469 - 472
  • [23] Selective cyclooxygenase-2 inhibitors: Design and synthesis
    Lei, XS
    Guo, ZR
    Qu, LB
    Zhu, QQ
    CHINESE CHEMICAL LETTERS, 1999, 10 (06) : 469 - 472
  • [24] Cyclooxygenase-2 selective inhibitors
    Cannon, GW
    DRUGS OF TODAY, 1999, 35 (07) : 487 - 496
  • [25] Selective cyclooxygenase-2 inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1999, 4 (07) : 334 - 335
  • [26] Cyclooxygenase-2 inhibitors and atherosclerosis
    Belton, O
    Fitzgerald, D
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) : 1820 - 1822
  • [27] The design and synthesis of novel cyclooxygenase-2 inhibitors
    Woods, KW
    McCroskey, RW
    Michaelides, MR
    Wada, CK
    Hulkower, KI
    Bell, RL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 92 - MEDI
  • [28] Cyclooxygenase-2 expression in NSCLC
    Kern, I.
    Sodja, E.
    Rot, M.
    VIRCHOWS ARCHIV, 2012, 461 : S65 - S65
  • [29] Cyclooxygenase-2 expression in chondrosarcoma
    Sutton, KM
    Wright, M
    Fondren, G
    Towle, CA
    Mankin, HJ
    ONCOLOGY, 2004, 66 (04) : 275 - 280
  • [30] Fluorophore-Labeled Cyclooxygenase-2 Inhibitors for the Imaging of Cyclooxygenase-2 Overexpression in Cancer: Synthesis and Biological Studies
    Bhardwaj, Atul
    Kaur, Jatinder
    Wuest, Frank
    Knaus, Edward E.
    CHEMMEDCHEM, 2014, 9 (01) : 109 - 116